BRPI1014039A2 - 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas - Google Patents

6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas

Info

Publication number
BRPI1014039A2
BRPI1014039A2 BRPI1014039A BRPI1014039A BRPI1014039A2 BR PI1014039 A2 BRPI1014039 A2 BR PI1014039A2 BR PI1014039 A BRPI1014039 A BR PI1014039A BR PI1014039 A BRPI1014039 A BR PI1014039A BR PI1014039 A2 BRPI1014039 A2 BR PI1014039A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
aza
bicyclo
hex
phenyl
Prior art date
Application number
BRPI1014039A
Other languages
English (en)
Inventor
Renneberg Dorte
Meyer Emmanuel
Caroff Eva
Hubler Francis
Hilpert Kurt
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI1014039A2 publication Critical patent/BRPI1014039A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1014039A 2009-04-08 2010-04-07 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas BRPI1014039A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009051486 2009-04-08
PCT/IB2010/051499 WO2010116328A2 (en) 2009-04-08 2010-04-07 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines

Publications (1)

Publication Number Publication Date
BRPI1014039A2 true BRPI1014039A2 (pt) 2018-04-03

Family

ID=42936647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014039A BRPI1014039A2 (pt) 2009-04-08 2010-04-07 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas

Country Status (18)

Country Link
US (1) US8288385B2 (pt)
EP (1) EP2417128B1 (pt)
JP (1) JP5536873B2 (pt)
KR (1) KR101694563B1 (pt)
CN (1) CN102369197B (pt)
AU (1) AU2010233378A1 (pt)
BR (1) BRPI1014039A2 (pt)
CA (1) CA2756542C (pt)
CL (1) CL2011002467A1 (pt)
ES (1) ES2567311T3 (pt)
IL (1) IL215517A0 (pt)
MA (1) MA33260B1 (pt)
MX (1) MX2011010200A (pt)
NZ (1) NZ596213A (pt)
RU (1) RU2011144763A (pt)
SG (1) SG175075A1 (pt)
WO (1) WO2010116328A2 (pt)
ZA (1) ZA201108158B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
EP2968737A4 (en) * 2013-03-15 2016-11-09 Concert Medical Llc METHOD AND SYSTEM FOR THE CONTROLLED ADMINISTRATION OF A FLUID TO A PATIENT AND / OR FOR THE CONTROLLED REMOVAL OF A FLUID FROM THE BODY OF THE PATIENT
SI3397631T1 (sl) * 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
TWI732031B (zh) 2016-08-31 2021-07-01 日商衛材R&D企管股份有限公司 吡唑并[1, 5-a]嘧啶化合物
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
CN113412260B (zh) 2019-01-29 2022-08-02 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
CA3141826A1 (en) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) * 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists

Also Published As

Publication number Publication date
CA2756542A1 (en) 2010-10-14
SG175075A1 (en) 2011-11-28
CL2011002467A1 (es) 2012-02-24
IL215517A0 (en) 2011-12-29
CN102369197A (zh) 2012-03-07
EP2417128A2 (en) 2012-02-15
US20120028989A1 (en) 2012-02-02
AU2010233378A1 (en) 2011-11-24
KR101694563B1 (ko) 2017-01-09
ZA201108158B (en) 2014-04-30
MX2011010200A (es) 2011-10-14
CA2756542C (en) 2017-08-22
JP5536873B2 (ja) 2014-07-02
WO2010116328A3 (en) 2011-01-13
RU2011144763A (ru) 2013-05-20
MA33260B1 (fr) 2012-05-02
EP2417128B1 (en) 2016-03-02
WO2010116328A2 (en) 2010-10-14
CN102369197B (zh) 2013-11-06
ES2567311T3 (es) 2016-04-21
NZ596213A (en) 2013-05-31
JP2012523406A (ja) 2012-10-04
US8288385B2 (en) 2012-10-16
KR20120070627A (ko) 2012-06-29

Similar Documents

Publication Publication Date Title
BRPI1014039A2 (pt) 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas
BRPI1006113A2 (pt) "derivado de piridina".
ME02397B (me) Pirazolo[1,5-a]pirimidini i -triazini kao antiviralni agensi
IL210176A0 (en) Substituted pyrimidone derivatives
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BR112012000763A2 (pt) derivados de piridin-4-ila
BRPI1013760A2 (pt) compostos anticâncer de amino pirimidina.
BRPI1011747A2 (pt) artigo não tecido funcionalizado.
EP2471786A4 (en) aminopyrazole derivative
BRPI0923497A2 (pt) derivados de piridazinona
BRPI1008948A2 (pt) nicotinamida substituída como moduladores kcnq2/3.
ZA201106663B (en) Fused pyrimidines
BRPI0914662A2 (pt) derivados de triazinona substituída
IL212636A0 (en) Pyridazinone derivatives
IL218481A0 (en) Herbicidal pyrimidone derivatives
BRPI0911161A2 (pt) derivado de piridazinona
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
PL2495243T3 (pl) Nowa pochodna 5-fluorouracylu
BRPI0914676A2 (pt) derivados de n-óxido de pirazina substituídos
DK2373644T3 (da) Pyridazinonderivater
BRPI1016192A2 (pt) derivados de soxazol.
BRPI0811094A2 (pt) Derivados de heteroarilamida pirimidona
EP2264026A4 (en) ALKYLAMINOPYRIDINDERIVATE
EP2502909A4 (en) aminopyridine derivative

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]